According to a report published by Allied Market Research, the global pancreatic cancer diagnostic market is experiencing significant growth driven by increasing cancer prevalence and advancements in diagnostic technologies. The market was valued at $1.6 billion in 2023 and is projected to reach $3.2 billion by 2035. The industry is expected to grow at a CAGR of 5.9% from 2024 to 2035.
Request Sample of the Report on Global Pancreatic Cancer Diagnostic Market 2035 –
https://www.alliedmarketresearch.com/request-sample/A124008
Prime determinants of growth
The growth of the pancreatic cancer diagnostic market is driven by increase in incidence of pancreatic cancer, rise in technological advancements in diagnostics, and growing awareness and early detection initiatives. However, high diagnostic cost is expected to restrain the growth of the pancreatic cancer diagnostic market. On the other hand, high growth potential in emerging countries provides lucrative opportunities for the market growth.
The consumables segment to maintain its leadership status throughout the forecast period
By product, the consumables segment held the largest market share in 2023, accounting for around three-fourths of the pancreatic cancer diagnostic market. This is attributed to the widespread use of consumables in various diagnostic procedures, including molecular testing, imaging, and biopsy analysis. Consumables such as reagents, kits, and assay products are essential for accurate and reliable testing, driving their high demand.
The imaging test segment to maintain its leadership status throughout the forecast period
By test type, the imaging test segment held the largest market share in 2023, accounting for more than two-fifths of the pancreatic cancer diagnostic market owing to its widespread use in detecting and staging pancreatic cancer, as well as monitoring treatment response. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound (EUS) play a crucial role in providing detailed visualization of pancreatic tumors.
The exocrine segment to maintain its leadership status throughout the forecast period
By cancer type, the exocrine segment held the largest market share in 2023, accounting for more than four- fifths of the pancreatic cancer diagnostic market and is expected to register the highest CAGR during the forecast period. This is attributed to high prevalence of exocrine pancreatic cancers, particularly pancreatic ductal adenocarcinoma (PDAC), which accounts for the majority of pancreatic cancer cases. Exocrine tumors are often diagnosed at advanced stages, necessitating extensive diagnostic testing, including imaging, biopsy, and molecular analysis.
Want to Explore More, Connect to our Analyst –
https://www.alliedmarketresearch.com/connect-to-analyst/A124008
The hospitals segment to maintain its leadership status throughout the forecast period
By end user, the hospitals segment held the largest market share in 2023, accounting for around half of the pancreatic cancer diagnostic market owing to availability of advanced diagnostic equipment, high volume of patient visits, and presence of skilled healthcare professionals. Hospitals serve as primary centers for cancer diagnosis and treatment, offering a comprehensive range of diagnostic modalities, including imaging, biopsy, and molecular testing.
North America held the largest market share in 2023
Region-wise, North America held the largest market share in 2023, accounting for more than two-fifths of the pancreatic cancer diagnostic market due to the presence of well-established healthcare infrastructure, advanced diagnostic technologies, and a high level of awareness about pancreatic cancer. North America, particularly the U.S., benefits from significant investments in cancer research, early detection programs, and access to cutting-edge diagnostic tools.
However, the Asia-Pacific is expected to witness the fastest CAGR of 6.6% from 2024 to 2035 owing to the increase in healthcare investments, improving healthcare infrastructure, and rise in awareness about early cancer detection. In addition, the growing incidence of pancreatic cancer, particularly in rapidly developing countries like China and India, is driving the demand for advanced diagnostic technologies.
For Purchase Related Queries/Inquiry –
https://www.alliedmarketresearch.com/purchase-enquiry/A124008
Major Key Players –
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• Fujifilm Holdings Corporation
• Randox Laboratories Ltd.
• Clearnote Health
• Siemens
• Prestige Biopharma Ltd.
• Toray Industries, Inc.
The report provides a detailed analysis of these key players in the pancreatic cancer diagnostic market. These players have adopted strategies such as product approval, agreement, collaboration, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to highlight the competitive scenario.
Frequently Asked Questions?
About Us –
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact Us:
United States
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int’l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
[email protected]
